诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

已收盘 04-30 16:08:13

13.830

+0.110

+0.80%

最高14.180	最低13.550	成交量708.10万
今开13.740	昨收13.720	日振幅4.59%
总市值243.68亿	流通市值206.62亿	总股本17.62亿
成交额9,781万	换手率0.47%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.83,"timestamp":1777536493009,"preClose":13.72,"halted":0,"volume":7081000,"delay":0,"changeRate":0.00801749271137022,"floatShares":1494000000,"shares":1762000000,"eps":0.38,"marketStatus":"已收盘","change":0.11,"latestTime":"04-30 16:08:13","open":13.74,"high":14.18,"low":13.55,"amount":97811515,"amplitude":0.045918,"askPrice":13.83,"askSize":32000,"bidPrice":13.81,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":0.469,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":5,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.72,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.778663,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":26.65,"timestamp":1777532400000,"preClose":26.8,"halted":0,"volume":8537800,"delay":0,"premium":"-54.74"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2630347483","title":"港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347483","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347483?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:51","pubTimestamp":1777341060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华(09969)涨近3%，截至发稿，涨2.67%，报14.24港元，成交额2919.93万港元。消息面上，4月27日，据诺诚健华官微消息，公司宣布，自研新型BCL2抑制剂Mesutoclax(ICP-248)和新型BTK抑制剂奥布替尼的多项研究成果入选2026年美国临床肿瘤学会(ASCO)年会。其中，Mesutoclax治疗髓系恶性肿瘤的研究入选口头报告，Mesutoclax治疗B细胞恶性肿瘤的研究入选海报展示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688428","BK4585","BK4588","BK1574","BK0239","09969","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630236060","title":"诺诚健华（688428）披露2026年股东周年大会通知，4月27日股价下跌1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630236060","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630236060?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:36","pubTimestamp":1777286164,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，诺诚健华报收于27.91元，较前一交易日下跌1.97%，最新总市值为492.51亿元。该股当日开盘28.0元，最高28.3元，最低27.17元，成交额达3.52亿元，换手率为4.75%。近日，诺诚健华医药有限公司发布《关于召开2026年股东周年大会的通知》。公告显示，公司将于2026年6月16日召开2026年股东周年大会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","688428","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630805801","title":"每周股票复盘：诺诚健华（688428）Q1营收5.29亿元同比增长38.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630805801","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630805801?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:02","pubTimestamp":1777140138,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，诺诚健华报收于28.47元，较上周的30.8元下跌7.56%。本周，诺诚健华4月20日盘中最高价报31.35元。本周关注点来自业绩披露要点：诺诚健华2026年一季报显示，一季度公司主营收入5.29亿元，同比上升38.65%。当前公司经营正常，商业化销售持续放量，研发管线推进顺利，2026年第一季度药品销售收入4.50亿元，同比增长44.54%，总营业收入5.29亿元，同比增长38.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600000624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149192906","title":"诺诚健华授予董事股份购回授权，规模达已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149192906","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149192906?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:32","pubTimestamp":1777041153,"startTime":"0","endTime":"0","summary":"诺诚健华于最新股东大会上宣布，其董事会获一般授权在适用法规及上市规则允许范围内，回购最多相当于公司已发行股份总数10%的股份。该授权同时包括自库存再出售或转让持有的股份，涵盖香港上市股份及于上海上市的人民币股份。公司董事会认为，适度购回股份有利于维护股东权益，并有望在适当时机提升每股价值回报。诺诚健华亦提及，公司过去十二个月内最高及最低市场价分别约为每股20.62港元和6.89港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺诚健华授予董事股份购回授权，规模达已发行股本10%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629244844","title":"诺诚健华(09969)授出1538.92万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2629244844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629244844?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:18","pubTimestamp":1777036724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2026年4月24日，公司根据2023年股权激励计划向3名承授人授出1538.92万份受限制股份单位，相当于公司于本公告日期已发行股份总数(不包括库存股份)约0.87%。向相关执行董事授出受限制股份单位受限于及须待股东于应届股东周年大会批准后，方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK0239","BK1161","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629084938","title":"诺诚健华：公司预计2026年药品销售收入将继续稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2629084938","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629084938?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:47","pubTimestamp":1777031220,"startTime":"0","endTime":"0","summary":"证券日报网4月24日讯，诺诚健华在接受调研者提问时表示，2026年第一季度，公司药品销售增长主要来自于核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增贡献，在三款产品组合驱动下，公司预计2026年药品销售收入将会继续稳健增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243718356725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","BK0239","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","02637","BK1589","159992","LU2097828805.USD","BK1574","LU2328871848.SGD","06990","BK1161","BK1191","LU0196878994.USD","LU2488822045.USD","01801","LU2097828631.EUR","LU2097828474.EUR","06855","LU2242644610.SGD","HK0000165453.HKD","BK1583","BK1515","LU2097828714.EUR","09969","LU0502904849.HKD","01672","01477","LU2097828557.USD","LU1969619763.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167499243","title":"异动解读 | 诺诚健华盘中大涨5.11%，一季度净利润暴增488.93%提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1167499243","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167499243?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:35","pubTimestamp":1776998105,"startTime":"0","endTime":"0","summary":"诺诚健华今日盘中股价大幅拉升，涨幅达到5.11%，引起市场关注。消息面上，公司此前发布了2026年第一季度业绩报告，业绩表现极为亮眼。报告显示，公司第一季度实现营业收入5.29亿元，同比增长38.65%；归属于上市公司股东的净利润达到1.06亿元，同比大幅增长488.93%。公司表示，其商业化体系已趋于成熟，研发管线推进顺利，未来将保持高质量增长。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629486467","title":"智通港股早知道 | 碳达峰碳中和综合评价考核办法印发 诺诚健华(09969)一季度归母净利润同比增加488.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629486467","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629486467?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:21","pubTimestamp":1776986463,"startTime":"0","endTime":"0","summary":"中共中央办公厅、国务院办公厅印发《碳达峰碳中和综合评价考核办法》中共中央办公厅、国务院办公厅印发《碳达峰碳中和综合评价考核办法》。权益变动后，宁波联创持有公司股份比例由6.23%降至4.96%，不再具有大股东身份。诺诚健华发布第一季度业绩，归母净利润1.06亿元 同比增加488.93%诺诚健华发布2026年第一季度报告，该集团取得营业收入5.29亿元，同比增加38.65%;归属于上市公司股东的净利润1.06亿元，同比增加488.93%;基本每股收益0.06元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","159790","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629486439","title":"复星医药筹划出售资产；诺诚健华一季度净利润同比增长488.93%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629486439","media":"每日经济新闻","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629486439?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985208,"startTime":"0","endTime":"0","summary":"｜2026年4月24日星期五｜NO.1九洲药业一季度净利润1.72亿元同比减少31.22%4月23日，九洲药业公告，公司2026年第一季度实现营业收入12.01亿元，同比下降19.43%；利润总额2.20亿元，同比下降29.20%；归属于上市公司股东的净利润1.72亿元，同比减少31.22%，主要系销售业务减少所致；经营活动产生的现金流量净额1.36亿元，同比下降52.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716839096.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716839096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","600196","02196","159938","09939","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852312","title":"图解诺诚健华一季报：第一季度单季净利润同比增长488.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852312","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852312?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:22","pubTimestamp":1776968577,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华2026年一季报显示，一季度公司主营收入5.29亿元，同比上升38.65%；归母净利润1.06亿元，同比上升488.93%；扣非净利润9592.96万元，同比上升5927.02%；负债率29.09%，投资收益546.98万元，财务费用-2196.33万元，毛利率88.14%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400006049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110509030","title":"诺诚健华2026年第一季度营收5.29亿元，净利润0.96亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110509030","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110509030?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:54","pubTimestamp":1776941676,"startTime":"0","endTime":"0","summary":"根据公司公告，诺诚健华2026年第一季度营业收入约为5.29亿元，同比增长38.65%。其中药品销售收入4.50亿元，同比增长44.54%。同期，公司扣除非经常性损益后净利润约为0.96亿元，同比增长5927.02%。公司经营活动产生的现金流量净额约为0.04亿元，同比减少92.53%。研发投入为2.29亿元，同比增长10.38%，占营业收入比例为43.35%，较上年同期下降11.10个百分点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺诚健华2026年第一季度营收5.29亿元，净利润0.96亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629780833","title":"诺诚健华：2026年一季度盈利1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629780833","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629780833?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:51","pubTimestamp":1776941460,"startTime":"0","endTime":"0","summary":"南方财经4月23日电，生物医药企业诺诚健华（09969.HK/688428.SH）披露2026年一季报，2026年第一季度药品收入同比增长44.5%至4.5亿元，由于药品收入的持续上涨以及全球商务拓展（BD），公司2026年第一季度总收入同比增长38.7%至5.3亿元，同期净利润1.0亿元。在此之前，公司于2025年首次实现年度盈利，归母净利润6.42亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716270246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","BK1574","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166871854","title":"诺诚健华2025年度收入激增并成功扭亏 聚焦血液瘤与免疫疾病多元管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1166871854","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166871854?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:41","pubTimestamp":1776940869,"startTime":"0","endTime":"0","summary":"诺诚健华于2025年度实现收入约人民币23.75亿元，同比上升约135.3%，主要得益于核心产品商业化能力的提升以及血液瘤、自身免疫疾病等领域多条在研产品管线的持续推进。公司当年由亏转盈，年内利润达人民币6.44亿元，相较2024年度亏损人民币4.53亿元出现显著改善，每股由亏转盈至人民币0.38元。整体来看，诺诚健华在2025年显著扩大收入规模并实现盈利能力转折，血液瘤与免疫疾病多元管线的商业化进展和全球化布局成为主要增长动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺诚健华2025年度收入激增并成功扭亏 聚焦血液瘤与免疫疾病多元管线","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629942887","title":"诺诚健华：一季度净利润1.06亿元 同比增长488.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629942887","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629942887?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:55","pubTimestamp":1776938113,"startTime":"0","endTime":"0","summary":"诺诚健华(688428)4月23日披露一季报，公司2026年一季度实现营业收入5.29亿元，同比增长38.65%；归母净利润1.06亿元，同比增长488.93%，主要系公司核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增贡献以及公司与Zenas的授权许可协议完成后续里程碑交付。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233716186676.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716186676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192469561","title":"异动解读 | 生物医药板块整体承压，诺诚健华盘中大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192469561","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192469561?lang=zh_cn&edition=full","pubTime":"2026-04-23 11:05","pubTimestamp":1776913548,"startTime":"0","endTime":"0","summary":"诺诚健华今日盘中股价大幅下跌5.04%，引起了市场的关注。消息面上，今日生物医药板块整体表现疲软，板块内多只个股出现下跌，诺诚健华也受到拖累。有分析指出，近期制药行业表现一般，板块整体承压可能是导致此次下跌的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629037318","title":"谢治宇一季度最新持仓披露！加码化工与储能","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629037318?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:31","pubTimestamp":1776778295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月21日，知名基金经理谢治宇管理的基金公布了一季报。以兴全合润为例，谢治宇在一季度进行了明确的行业切换。此外，晶晨股份亦获得小幅增持。减持方面，中际旭创持仓数量由约344万股缩减至约213万股，减持幅度显著。基金一季度对海外算力、半导体设备、储能以及化工板块进行了重点配置，部分化工龙头经历了格局的重塑与分化后将重新走向上升通道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097829019.USD","605117","IE0032431581.USD","LU0456842615.SGD","01801","LU0456827905.SGD","LU1102505762.USD","000683","LU0588545490.SGD","ALBmain","002008","LU0561508036.HKD","LU0979878070.USD","688120","688099","LU1993786604.SGD","LU1720050803.USD","600160","LU1880383366.USD","03750","LU0531971595.HKD","300750","LU2213484517.USD","02423","BABA","EVS.SI","SG9999001689.USD","LU0359201885.HKD","89988","LU0345776255.USD","LU0572940350.SGD","LU1979443071.USD","LU0192582467.USD","BK0229","688008","BK1097","SG9999001903.USD","LU2476274720.SGD","LU0348783662.USD","SG9999006514.SGD","LU2097828805.USD","09969","BK1618","09988","LU0169518387.USD","300308","LU2580892789.USD","LU0231483743.USD","HBBD.SI","600426"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628775930","title":"每周股票复盘：诺诚健华（688428）将召开2026年Q1业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2628775930","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628775930?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:29","pubTimestamp":1776536946,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，诺诚健华报收于30.8元，较上周的28.89元上涨6.61%。本周，诺诚健华4月16日盘中最高价报31.91元。4月13日盘中最低价报28.15元。诺诚健华当前最新总市值543.51亿元，在化学制药板块市值排名9/150，在两市A股市值排名372/5198。参会人员包括董事会主席兼行政总裁Jisong Cui博士、独立非执行董事胡兰女士、首席财务官傅欣先生及信息披露境内代表袁蓓女士。说明会后可通过该平台查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688428","BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627238931","title":"诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238931","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627238931?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:05","pubTimestamp":1776261917,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，诺诚健华报收于31.17元，较前一交易日上涨7.93%，最新总市值为550.04亿元。该股当日开盘29.49元，最高31.82元，最低28.88元，成交额达6.28亿元，换手率为7.74%。公告显示，公司将于2026年4月24日上午11:00-12:00通过上证路演中心网络互动方式召开2026年第一季度业绩说明会，介绍公司当季经营成果及财务状况。投资者可于4月17日至4月23日16:00前通过上证路演中心网站或公司邮箱IR@innocarepharma.com提交问题。说明会后可通过该平台查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500042904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK1161","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625934106","title":"诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2625934106","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625934106?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:14","pubTimestamp":1775556840,"startTime":"0","endTime":"0","summary":"证券日报网讯4月7日，诺诚健华在互动平台回答投资者提问时表示，截至2026年3月20日公司A股股东户数约为1.93万户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696569528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","399300","159982","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0773},{"period":"1month","weight":0.0044},{"period":"3month","weight":0.1807},{"period":"6month","weight":-0.0372},{"period":"1year","weight":0.3971},{"period":"ytd","weight":0.1154}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.101305},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}